Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline
The use of zebrafish larvae in basic and applied research has grown exponentially during the last 20 years. The reasons for this success lay in its specific experimental advantages: on the one hand, the small size, the large number of progeny and the fast life cycle greatly facilitate large-scale ap...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.00703/full |
id |
doaj-fb9ae8a1ef6e4c25be96eb2b2c925cf1 |
---|---|
record_format |
Article |
spelling |
doaj-fb9ae8a1ef6e4c25be96eb2b2c925cf12020-11-25T00:13:41ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122018-07-01910.3389/fphar.2018.00703384372Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery PipelineCarles CornetVincenzo Di DonatoJavier TerrienteThe use of zebrafish larvae in basic and applied research has grown exponentially during the last 20 years. The reasons for this success lay in its specific experimental advantages: on the one hand, the small size, the large number of progeny and the fast life cycle greatly facilitate large-scale approaches while maintaining 3Rs amenability; on the other hand, high genetic and physiological homology with humans and ease of genetic manipulation make zebrafish larvae a highly robust model for understanding human disease. Together, these advantages allow using zebrafish larvae for performing high-throughput research, both in terms of chemical and genetic phenotypic screenings. Therefore, the zebrafish larva as an animal model is placed between more reductionist in vitro high-throughput screenings and informative but low-throughput preclinical assays using mammals. However, despite its biological advantages and growing translational validation, zebrafish remains scarcely used in current drug discovery pipelines. In a context in which the pharmaceutical industry is facing a productivity crisis in bringing new drugs to the market, the combined advantages of zebrafish and the CRISPR/Cas9 system, the most powerful technology for genomic editing to date, has the potential to become a valuable tool for streamlining the generation of models mimicking human disease, the validation of novel drug targets and the discovery of new therapeutics. This review will focus on the most recent advances on CRISPR/Cas9 implementation in zebrafish and all their potential uses in biomedical research and drug discovery.https://www.frontiersin.org/article/10.3389/fphar.2018.00703/fullCRISPR/Cas9drug discoveryzebrafishdisease modelphenotypic drug screeningfunctional genomics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Carles Cornet Vincenzo Di Donato Javier Terriente |
spellingShingle |
Carles Cornet Vincenzo Di Donato Javier Terriente Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline Frontiers in Pharmacology CRISPR/Cas9 drug discovery zebrafish disease model phenotypic drug screening functional genomics |
author_facet |
Carles Cornet Vincenzo Di Donato Javier Terriente |
author_sort |
Carles Cornet |
title |
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline |
title_short |
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline |
title_full |
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline |
title_fullStr |
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline |
title_full_unstemmed |
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline |
title_sort |
combining zebrafish and crispr/cas9: toward a more efficient drug discovery pipeline |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2018-07-01 |
description |
The use of zebrafish larvae in basic and applied research has grown exponentially during the last 20 years. The reasons for this success lay in its specific experimental advantages: on the one hand, the small size, the large number of progeny and the fast life cycle greatly facilitate large-scale approaches while maintaining 3Rs amenability; on the other hand, high genetic and physiological homology with humans and ease of genetic manipulation make zebrafish larvae a highly robust model for understanding human disease. Together, these advantages allow using zebrafish larvae for performing high-throughput research, both in terms of chemical and genetic phenotypic screenings. Therefore, the zebrafish larva as an animal model is placed between more reductionist in vitro high-throughput screenings and informative but low-throughput preclinical assays using mammals. However, despite its biological advantages and growing translational validation, zebrafish remains scarcely used in current drug discovery pipelines. In a context in which the pharmaceutical industry is facing a productivity crisis in bringing new drugs to the market, the combined advantages of zebrafish and the CRISPR/Cas9 system, the most powerful technology for genomic editing to date, has the potential to become a valuable tool for streamlining the generation of models mimicking human disease, the validation of novel drug targets and the discovery of new therapeutics. This review will focus on the most recent advances on CRISPR/Cas9 implementation in zebrafish and all their potential uses in biomedical research and drug discovery. |
topic |
CRISPR/Cas9 drug discovery zebrafish disease model phenotypic drug screening functional genomics |
url |
https://www.frontiersin.org/article/10.3389/fphar.2018.00703/full |
work_keys_str_mv |
AT carlescornet combiningzebrafishandcrisprcas9towardamoreefficientdrugdiscoverypipeline AT vincenzodidonato combiningzebrafishandcrisprcas9towardamoreefficientdrugdiscoverypipeline AT javierterriente combiningzebrafishandcrisprcas9towardamoreefficientdrugdiscoverypipeline |
_version_ |
1725393640827650048 |